Background: Atazanavir plus raltegravir 300/400 mg twice daily is being explored as a ritonavir-and nucleoside-sparing treatment strategy. The pharmacokinetics and safety of this combination in healthy individuals were evaluated. Methods: A total of 22 healthy individuals received raltegravir 400 mg on days 1-5, atazanavir 300 mg on days 6-12 and atazanavir plus raltegravir 300/400 mg on days 13-26, twice daily with a light meal. Serial blood samples were collected 12 h after the morning dose on days 5, 12 and 26; safety assessments, clinical laboratory data and serial electrocardiograms (ECGs) at 0, 2 and 6 h were obtained. Results: Raltegravir coadministration reduced atazanavir geometric mean maximum plasma concentration (C max ), area under the plasma concentration-time curve from 0 to 12 h post-dose (AUC 0-12 ) and trough plasma concentration (C min ) by 11%, 17% and 29%, respectively, compared with atazanavir alone. Geometric mean atazanavir C min was 817 ng/ml (range 250-1,550) with raltegravir coadministration. Atazanavir increased raltegravir geometric mean C max , AUC 0-12 and C min by 39%, 54% and 48%, respectively. All adverse events were of mild or moderate intensity. Hyperbilirubinaemia and ECG PR increases with atazanavir were similar to those of atazanavir/ritonavir once daily. No corrected QT prolongations were noted. Mean QRS increase from baseline was 11.0 ms (range 2-25) after receiving atazanavir for 7 days; no further QRS increase was noted and no QRS interval was >120 ms with raltegravir coadministration. No ECG changes were observed with raltegravir alone. Conclusions: Coadministration of atazanavir and raltegravir 300/400 mg twice daily decreased atazanavir AUC 0-12 and C min relative to atazanavir alone, and increased AUC 0-12 of raltegravir relative to raltegravir alone. Atazanavir and raltegravir alone and coadministered appeared safe and well-tolerated.
Atazanavir (ATV) is a potent inhibitor of HIV type-1 (HIV-1) protease. When boosted with ritonavir (RTV) 100 mg and combined with other antiretrovirals, the protease inhibitor ATV, at a dosage of 300 mg once daily, has been shown to be highly effective and well-tolerated in both treatment-naive and treatment-experienced adult patients. In the US, a 400 mg unboosted once-daily dose is indicated in antiretroviral-naive patients who cannot tolerate RTV [1] [2] [3] [4] . Raltegravir (RAL) belongs to a novel antiretroviral class that potently and selectively inhibits HIV-1 integrase. At a dosage of 400 mg twice daily, RAL, in combination with two nucleoside reverse transcriptase inhibitors (NRTIs), is indicated for the treatment of HIV-1 infection in treatment-experienced and treatment-naive adult patients [5, 6] . For optimum efficacy, protease inhibitors are generally recommended for use with RTV as a pharmacokinetic enhancer in a regimen that also includes two NRTIs for highly active combination therapy [7] .
The use of NRTIs, however, might be limited by adverse events. In particular, stavudine and zidovudine are associated with lipoatrophy [8] , and renal impairment [9, 10] and decreased bone mineral density [11] Original article Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals Li Introduction have been reported with the use of tenofovir disoproxil fumarate. As a result, nucleoside-sparing proteaseinhibitor-containing regimens have been investigated. Furthermore, the use of RTV-boosted protease inhibitors can complicate patient management through pharmacokinetic interactions between RTV and comedications [12] and possible adverse events associated with RTV (particularly diarrhoea, and worsened lipid and glucose parameters) [13] . Use of RTV can also increase inconvenience to the patient, as the currently available RTV capsules are large, require refrigeration and add more pills to the daily regimen. Thus, regimens that do not use NRTIs or RTV represent attractive options that might minimize long-term complications associated with antiretroviral treatments and help improve patient compliance. Both ATV and RAL are individually well-tolerated, with low rates of gastrointestinal intolerance and minimal effect on lipids [3, 4, 14] . Thus, this combination might also be associated with additional benefits of minimal gastrointestinal and lipid effects. Therefore, ATV 300 mg twice daily given with RAL 400 mg twice daily is being explored as an RTV-and nucleoside-sparing treatment strategy that also maintains the convenience of a two-pill, twice daily regimen.
The concept of achieving increased ATV exposure without the need for RTV boosting by dosing ATV twice daily has been previously tested in a dose-ranging study in healthy HIV-uninfected individuals [15] . The results demonstrated that among the doses studied (ATV 200, 300 and 400 mg twice daily), the pharmacokinetic and safety profiles of ATV 300 mg twice daily were most similar to those of ATV/RTV 300/100 mg once daily [15] , and this dose was therefore selected for the current study. ATV is a reversible inhibitor of uridine diphosphate glucuronosyltransferase (UGT1A1; K i approximately 1.9 µM) [16] , the dominant isoform that catalyses the glucuronidation of RAL [17] . In previously conducted studies in healthy individuals, coadministration of RAL with ATV 400 mg once daily or ATV/RTV 300/100 mg once daily resulted in a modest increase in RAL exposure (area under the plasma concentration-time curve [AUC] geometric mean ratios of 1.72 and 1.41, respectively), as predicted from the known metabolism of these drugs [18] ; however, the effects of RAL on the exposure of ATV were not investigated.
Given the known safety and tolerability profiles of ATV and RAL, an ATV plus RAL combination was expected to be safe and well-tolerated. Dose-related electrocardiogram (ECG) effects, mainly QRS and PR interval effects, have been observed with ATV administered twice daily [15] ; RAL, however, has previously been shown to have no ECG interval effects on corrected QT (QTc), PR and QRS at a supratherapeutic dose of 800 mg [19] . ATV is known to increase unconjugated bilirubin levels [20] , and in a previous study of twice-daily ATV doses in healthy individuals, the frequency of grade 3 and 4 total bilirubin was a dose-dependent effect of ATV. There were no safety signals, however, and ATV doses of 200-400 mg twice daily appeared to be well-tolerated [15] .
This study was conducted to assess the two-way pharmacokinetic interaction of ATV 300 mg twice daily coadministered with RAL 400 mg twice daily, the ECG effects of 300 mg ATV twice daily over 21 days, given with or without RAL 400 mg twice daily, and the safety and tolerability of coadministered ATV 300 mg twice daily and RAL 400 mg twice daily.
Methods

Study population and study design
This was an open-label, sequential, multiple-dose study in healthy HIV-uninfected individuals, and was conducted in accordance with Good Clinical Practice and the ethical principles of the Declaration of Helsinki. The protocol, amendments and informed consent received approval by the institutional review board/independent ethics committee at the study site. All participants were required to give written informed consent prior to participation in the study.
HIV-uninfected men or women aged 18-45 years with a body mass index of 18-32 kg/m 2 were eligible for inclusion in the study if, at screening, they had a QTc interval ≤450 ms, PR interval ≤200 ms, QRS interval ≤100 ms and normal ECG waveforms on a 12-lead ECG. Health was otherwise determined by medical history, physical examination and clinical laboratory evaluations. Women of childbearing potential must have been using an acceptable method of contraception for ≥1 month before dosing (with a negative pregnancy test within 48 h prior to dosing with study medication). Women who were nursing or pregnant were excluded from the study.
Each participant was administered RAL (Isentress ® ; Merck & Co., Inc., Whitehouse Station, NJ, USA) 400 mg twice daily for 5 days, with only the morning dose administered on day 5, then ATV (Reyataz ® ; Bristol-Myers Squibb, Princeton, NJ, USA) 300 mg twice daily for 7 days, followed by ATV 300 mg twice daily coadministered with RAL 400 mg twice daily for 14 days. Study drugs were administered within 5 min of completing a light meal (277 kcal). Participants were screened and enrolled within 21 days before day 1, and returned for a follow-up visit and discharge 10-14 days after day 26.
Pharmacokinetic sample collection and analyses
Serial plasma samples for pharmacokinetic analysis were collected on days 5, 12 and 26 at predose (0 h), 1, 2, 3, 4, 6, 8 and 12 h after the morning dose. On day 5, an additional blood sample was collected for UGT1A1 genetic analysis. Pharmacokinetic samples were assayed using liquid chromatography tandem mass spectrometry [21, 22] .
The standard curve range for ATV was 10-10,000 ng/ ml, with between-run percentage coefficient of variation (%CV)≤3.33 and within-run %CV≤4.73. The standard curve range for RAL was 2-1,000 ng/ml, with betweenrun %CV≤8.1 and within-run %CV≤1.5.
Steady-state pharmacokinetic parameters were derived by non-compartmental analysis using the validated computer programme Kinetica™ (version 4.4.1; Thermo Electron Corporation, Philadelphia, PA, USA). Plasma concentration versus time data were used to analyse maximum plasma concentration (C max ), AUC from 0 to 12 h post-dose (AUC 0-12 ), trough plasma concentration (C min ) at 12 h post morning dose, plasma concentration at time zero (C 0 ; that is, plasma concentration before the morning dose) and time of maximum plasma concentration (T max ). The C max , C min , C 0 and T max were recorded directly from experimental observations for each treatment period. The AUC 0-12 was calculated by linear and log-linear trapezoidal summations using the mixed log-linear algorithm.
Safety analyses
All participants who received study drugs were included in the safety data set. Safety assessments were based on medical review of adverse event reports and results of vital sign measurements, ECGs, physical examinations and clinical laboratory tests. Safety profiles were obtained at screening, days -1, 5, 12, 26 and at discharge. Serial time-matched ECGs were obtained at 0, 2 and 6 h after the morning dose on days -1, 1, 5, 6, 8, 10, 12, 13, 15, 19, 22 and 26. ECG recordings were evaluated by the investigator and interpreted by a third-party ECG core laboratory (Cardiocore Lab, Inc. Bethesda, MD, USA) using standard semi-automatic over-read methods.
Statistical analyses
Pharmacokinetic parameters were summarized by treatment and analyte. The estimated ratios of geometric means and 90% confidence intervals (CIs) were generated for ATV and RAL C max , AUC 0-12 , C min and C 0 using general linear models on log-transformed data, with treatment as a fixed effect and measurements within each participant as repeated measurements. Point estimates and 90% CIs for differences at the log scale were exponentiated to obtain estimates and CIs for ratios of geometric means in the original scale. In the comparisons, ATV or RAL alone were used as the reference. No adjustments were made for multiple comparisons. It was to be concluded that RAL had no effect on ATV C max , AUC 0-12 and C min if the 90% CIs for the ratios of geometric means for the corresponding pharmacokinetic parameter were entirely contained within 0.8-1.25, the default no-effect boundary specified in the US Food and Drug Administration drug interaction study guidance [23] . Means and 95% CIs were derived for each ECG parameter and for their time-matched changes from baseline. These were used to assess the ECG effects of 300 mg ATV twice daily over 21 days. All statistical analyses were carried out using SAS/STAT ® (version 8.2; SAS Institute, Inc., Cary, NC, USA).
Results
A total of 22 participants received study drugs. Among them, 16 (73%) participants were male and 6 (27%) were female, with a mean age of 32 years. Overall, 10 (45%) participants were White, 10 were Black and 1 each (5%) were Asian or other ethnicity. The participants had a mean weight of 77.3 kg and a mean body mass index of 26.6 kg/m 2 . A total of 19 participants completed the study; 3 participants discontinued because of an adverse event following administration of ATV 300 mg plus RAL 400 mg twice daily. Of the 22 participants who received study drugs, 8 (36%) were homozygous carriers of the wild-type UGT1A1, 13 (59%) were heterozygous variant carriers and one was a homozygous carrier for Gilbert's syndrome UGT1A1*28/*28.
Pharmacokinetics
ATV plasma concentration-time profiles following ATV 300 mg twice daily alone and coadministered with RAL are shown in Figure 1A . ATV geometric mean C max , AUC 0-12 and C min were reduced by 11% (90% CI 6-16), 17% (90% CI [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] and 29% (90% CI 22-35), respectively, when coadministered with RAL compared with ATV 300 mg twice daily administered alone ( Table 1 ). The 90% CI for the ratio of geometric means for ATV C max was included within the prespecified no-effect interval of 0.80-1.25, whereas the lower bound of the 90% CI for ATV AUC 0-12 was just below 0.8. ATV C 0 decreased upon coadministration with RAL. The ATV T max (median 2.0 h) was unaffected by coadministration with RAL (Table 1) .
RAL plasma concentrations were increased by the coadministration of ATV ( Figure 1B) . RAL geometric mean C max , AUC 0-12 and C min were increased by 39% (90% CI -1-96), 54% (90% CI 14-108) and 48% (90% CI 8-102), respectively, following coadministration with ATV 300 mg twice daily (Table 1) . RAL C 0 increased upon coadministration with ATV (Table 1) . RAL concentration-time profiles exhibited a high degree of inter-and intrapatient variability. Both the high variability in T max (range 1-8 h) as well as the occurrence of multiple peaks in over two-thirds of participants resulted in a distinct secondary peak in the mean concentration-time profile ( Figure 1B) .
Safety
There were no serious adverse events in this study. All adverse events were of mild or moderate intensity. Three participants discontinued because of an adverse event following administration of ATV 300 mg plus RAL 400 mg (n=1, occasional premature ventricular contractions that began on day 19 and continued when study drug was withdrawn, considered unlikely to be related to the study drug by the investigator; n=1, generalized rash that began on day 14, considered mild and certainly related to study drug by the investigator; and n=1, generalized rash that began on day 15, considered mild and probably related to study drug by the investigator). The participant who was withdrawn because of premature ventricular contractions was a 26-year-old Black female, with no prior history of premature ventricular contractions, and normal atrial and ventricular function. The event lasted 5 days and resolved without treatment.
ATV 300 mg twice daily ATV 300 mg twice daily plus RAL 400 mg twice daily The incidence of adverse events following study drug administration was generally similar when ATV was administered alone and when ATV was coadministered with RAL, although more jaundice was reported among participants following administration of ATV alone than following administration of the combination (n=10 compared with n=6, respectively; Table 2 ). Total and indirect bilirubin levels were increased during periods of ATV dosing with or without coadministered RAL, compared with the RAL-alone period, but returned rapidly to baseline after the termination of administration of study drugs. Total bilirubin levels were slightly higher during the ATV-alone period than when ATV was given in combination with RAL (Table 2) , which is consistent with the changes in ATV exposures and suggests that RAL had little or no effect on ATV-associated hyperbilirubinaemia.
Electrocardiograms
For the duration of the study, mean QTc (corrected by Fridericia's formula [QTcF]) did not increase (Table 3) . During the ATV-alone dosing period, the mean PR and QRS intervals increased beginning after day 6; the PR and QRS intervals remained increased but relatively stable throughout the period when ATV was coadministered with RAL. The mean PR interval change from baseline at 2 h post-dose on day 12 was 37 ms (range 17-63) and on day 26 it was 31 ms (range 12-54; Table 3 ). The mean QRS change from baseline at 2 h post-ATV dose on day 12 was 11 ms (range 2-25), which was also the change from baseline at 2 h post-ATV dose on day 26 (range -2-25; Table 3 ). All changes were asymptomatic. RAL did not affect ATV-associated PR or QRS changes. The prolongation in PR interval was most pronounced at 2 h post-dose (Table 3 and Figure 2A) ; the QRS effect was similar to that pre-dose at either the 2 or 6 h postdose time points (Table 3 and Figure 2B ).
Discussion
Given the known efficacy and safety profiles of ATV and RAL, a combination of ATV 300 mg and RAL 400 mg, twice daily, is being explored as an RTV-and nucleoside-sparing option for the treatment of HIV-1 infection. This study reports the pharmacokinetics and safety of the twice-daily ATV 300 mg plus RAL 400 mg combination in healthy individuals.
In this study, the adjusted geometric mean C max , AUC 0-12 and C min of ATV were lower when ATV 300 mg twice daily was coadministered with RAL 400 mg twice daily, than when ATV 300 mg twice daily was administered alone. ATV C 0 decreased upon coadministration with RAL; the slope of the terminal phase appeared to be unchanged, suggesting the interaction was not related to metabolic induction ( Figure 1A) . ATV is primarily hepatically metabolized via the CYP3A4-mediated pathway [1] . RAL 400 mg twice daily at steady state was found to have no effect on the pharmacokinetics of midazolam, a sensitive CYP3A4 probe [5] . Thus, it is unlikely that the reduction in ATV exposure upon coadministration with RAL was the result of an induction of CYP3A4. Both ATV and RAL, either administered alone or in combination, were dosed with a light meal in this study. Although RAL can be given without regard to food, administration with a meal optimizes ATV bioavailability by enhancing its systemic exposure and reducing its pharmacokinetic variability [1, 5] . ATV is formulated as a bisulphate salt, and its solubility decreases as the pH increases [1] . Thus, its bioavailability is highly sensitive to the perturbations of intragastric acidity, with lower bioavailability as intragastric pH increases. RAL is a weak acid, but is a basic potassium salt in its current formulation [5] . Therefore, it is conceivable that an increase in pH in the immediate vicinity of a dissolving ATV particle or an acid-base reaction might lead to a decrease in ATV's in vivo solubility, and consequently its bioavailability. Such a pH effect would therefore be consistent with the observed apparent uniform reduction in ATV mean concentration-time profiles; however, the precise mechanism behind the observed reduction in ATV exposures following coadministration with RAL remains unknown.
Despite the reductions in ATV exposures seen when coadministered with RAL, all individual ATV C min values at the end of the study were above the 10-fold population mean protein binding adjusted drug concentration that provides 90% of maximal effect (EC 90 ) against wild-type HIV-1 (140 ng/ml; EC 90 =14 ng/ml); the lowest individual ATV C min was 250 ng/ml, suggesting that the ATV 300 mg twice-daily dose in combination with RAL 400 mg twice daily would be clinically efficacious. This study was conducted in HIV-uninfected individuals. ATV concentrations have been reported to be lower in HIV-1-infected patients than in HIV-uninfected individuals [24] . Although the mechanism underlying these differences in Table 3 . ECG intervals with RAL 400 mg, ATV 300 mg and ATV plus RAL combined, twice daily at 2 h post-dose and change from baseline a The absolute value is the value at 2 h post-dose. ATV, atazanavir; ECG, electrocardiogram; QTcF, QT corrected by Fridericia's formula; RAL, raltegravir. 407 (15) 402 (14) 398 (14) 394 (13 Mean ±se change from baseline in (A) PR interval and (B) QRS interval by study day. Dosing periods were raltegravir 400 mg on days 1-5, atazanavir 300 mg on days 6-12 and atazanavir plus raltegravir 300/400 mg on days 13-26. ATV exposure is not known, it is thought to be in part ascribed to decreased gastric acid output and, therefore, higher intragastric pH in HIV-1-infected patients relative to HIV-uninfected individuals [25] [26] [27] . If the effect of RAL on ATV is through an acid-base interaction during absorption, one might expect to observe a somewhat smaller extent of interaction in HIV-1-infected patients because of their higher baseline gastric pH. A study of ATV plus RAL twice daily pharmacokinetics in HIV-1-infected patients is underway.
The adjusted geometric mean ATV AUC 0-24 (calculated as 2×AUC 0-12 =61,812 ng•h/ml) and C min (1,166 ng/ml) after administration of ATV 300 mg twice daily alone were similar to historical values observed in healthy individuals after ATV/RTV 300/100 mg once daily (AUC 0-24 =57,039 ng•h/ml and C min =1,227 ng/ml) [1] . Exposures from ATV 300 mg twice daily in this study, however, were somewhat higher than those observed in healthy individuals following the same treatment (ATV 300 mg twice daily) in a previous study (AUC 0-24 =46,451 ng•h/ml and C min =705 ng/ml) [15] . The reasons for the difference in absolute values between the two studies are unknown. The crossover study design and within-study comparisons employed in the current study allow for accurate characterization of the interactions between ATV and RAL when given in combination.
Following RAL administration alone on day 5 and administration of RAL in combination with ATV on day 26, there were no apparent correlations between RAL pharmacokinetics and UGT1A1 genotype. Like ATV, RAL pharmacokinetics in the current formulation are substantially affected by gastric pH [5] , which changes in the presence or absence of food. RAL pharmacokinetic variability in this study was consistent with previous studies in which RAL is dosed with food [5] . RAL exposures were increased when given in combination with ATV 300 mg twice daily, as predicted given the potent inhibition of UGT1A1 by ATV. Similar results were previously observed when RAL was concomitantly administered with ATV 400 mg once daily or ATV/RTV 300/100 mg once daily [18] . Because the primary mechanism of RAL clearance in humans is UGT1A1-mediated metabolism, it is unclear if the polymorphic expression of UGT1A1 could influence the pharmacokinetic interactions between ATV and RAL.
A previous study investigating the pharmacokinetics and safety of ATV doses from 200-400 mg twice daily (in the absence of RTV), showed that ATV did not prolong the QTcF [15] . Our findings are in agreement with this study, and no QTcF prolongations with ATV were observed in either study. Consistent with previous reports (from a study of RAL 800 mg) [19] , RAL in the present study was not associated with any ECG interval effects. With respect to ECG effects associated with ATV in the present study, mean QRS and PR interval increases were observed with ATV alone, and both intervals remained prolonged throughout coadministration with RAL. By contrast, RAL administration did not appear to affect ATV-associated PR or QRS changes. The prolongation of the PR interval was most pronounced at approximately the time of ATV C max (2 h post-dose), whereas the QRS effect was similar at all three time points evaluated, suggesting that the QRS changes might be less associated with ATV C max .
When administered in a once-daily regimen with or without RTV, ATV has been shown to prolong PR intervals in a dose-or concentration-dependent manner. This effect is generally asymptomatic and limited to firstdegree AV block [1] . The prolongation of PR intervals observed in this study is similar to or slightly greater than that derived from historical data after administration of ATV/RTV 300/100 mg once daily [1] . However, the QRS interval changes observed historically with ATV/RTV 300/100 mg once daily have been minimal (mean increase of ≤3 ms). A previous study investigating the pharmacokinetics and safety of ATV doses from 200-400 mg twice daily (in the absence of RTV) showed dose-and concentration-related mean QRS prolongation [15] . In this prior study, the QRS interval increased by a mean of approximately 10 ms at a dose of 300 mg twice daily; in 17 of 18 participants maximum QRS was <120 ms. In one participant, the QRS was between 120 ms and 130 ms; of note, however, increases from baseline were <25% in all 18 participants. The investigation in the current study on the ECG changes associated with ATV administered twice daily in the absence of RTV confirmed the previously observed QRS prolongation. The specific mechanism underlying the effect is unknown. The observation that the exposures of ATV following 300 mg twice-daily dosing are not higher than historical values following treatment with ATV/ RTV 300/100 mg once daily in healthy individuals [1] suggests that the QRS changes might be associated with increased ATV metabolites in the absence of RTV. The clinical relevance of QRS interval increases with ATV twice daily is unknown, and is being investigated further in a Phase II pilot safety and efficacy study, in which ATV 300 mg and RAL 400 mg are administered twice daily to HIV-1-infected patients in comparison to ATV/RTV 300/100 mg once daily in combination with emtricitabine and tenofovir disoproxil fumarate.
In the current study, ATV twice daily and RAL twice daily alone and when coadministered were generally safe and well-tolerated; in particular, RAL coadministration did not appear to increase ATV-associated hyperbilirubinaemia, which might be a result of the lower ATV exposure observed in the RAL plus ATV coadministration arm. The incidence of hyperbilirubinaemia was similar after ATV 300 mg twice daily alone or in the presence of RAL 400 mg twice daily.
In conclusion, coadministration of ATV 300 mg and RAL 400 mg twice daily decreased ATV AUC 0-12 and C min relative to ATV administered alone, and increased AUC 0-12 of RAL relative to RAL administered alone. In this study, ATV and RAL alone and coadministered appeared safe and well tolerated. The pharmacokinetic and safety profiles of the twice-daily combination of ATV 300 mg with RAL 400 mg in this study in HIVuninfected healthy volunteers provides support for further clinical investigation of this nucleoside-and RTVsparing regimen in HIV-infected patients.
